Screener Summaries Updates Institutions Sign In More Updates › Other Events › BDX Other Events · Apr 2, 2026
Following the spin-off of its Biosciences and Diagnostic Solutions business, Becton, Dickinson and Company has… BDX Becton Dickinson & Co
Following the spin-off of its Biosciences and Diagnostic Solutions business, Becton, Dickinson and Company has furnished recast historical financial information to provide a baseline for its continuing operations. This recast data presents the former business as discontinued operations, allowing investors to more accurately assess the standalone performance and year-over-year trends of the remaining business.
More from Becton Dickinson & Co BD reports Q4 revenue of $5.3B and FY adjusted EPS of $12.70 Nov 5, 2026 Becton, Dickinson and Company reported third fiscal quarter results ending June 30, 2026, with revenue of $4.98… Aug 6, 2026 Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments… Jul 22, 2026 Becton, Dickinson and Company has resumed shipments of ChloraPrep in the U.S. following the completion of additional… May 29, 2026 Becton, Dickinson and Company's subsidiary issued €600 million in 3.855% notes due 2033 to refinance existing debt May 20, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
